Ireland - English - HPRA (Health Products Regulatory Authority)

dermal laboratories ltd - hydrocortisone; lidocaine hydrochloride - cutaneous spray, solution - 0.2/1.0 percent weight/weight - corticosteroids; hydrocortisone

Ireland - English - HPRA (Health Products Regulatory Authority)

dermal laboratories (ireland) limited - hydrocortisone; lidocaine hydrochloride - cutaneous spray, solution - 0.2/1.0 percent weight/weight - corticosteroids; hydrocortisone

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - lidocaine hydrochloride 30 mg in 1 g - product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. these products are contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindica

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - lidocaine hydrochloride anhydrous 30 mg in 1 g - product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. these products are contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pregnancy category c. reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. there are, however, no adequate and well-controlled studies in pregnant women. animal reproduction studies are not always predictive of human response. general consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. the more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. there are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. safety and efficacy in children have not been established.

United States - English - NLM (National Library of Medicine)

puretek corporation - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - lidocaine hydrochloride anhydrous 30 mg in 1 g - product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution in patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. product is contraindicated for tuberculous or fungal lesions of skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindicated in t

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - intramuscular where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia

United States - English - NLM (National Library of Medicine)

proficient rx lp - lidocaine hydrochloride anhydrous (unii: ec2cnf7xfp) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - where oral therapy is not feasible, injectable corticosteroid therapy, including kenalog-40 injection (triamcinolone acetonide injectable suspension, usp) is indicated for intramuscular use as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, n

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 30 mg in 1 g

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. this product is contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pregnancy category c. reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. there are, however, no adequate and well-controlled studies in pregnant women. animal reproduction studies are not always predictive of human response. general consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. the more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. there are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. safety and efficacy in children have not been established.

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. if excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. product should be used with caution on patients receiving antiarrhythmic drugs of class i since the adverse effects are additive and generally synergistic. these products are contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pregnancy category c. reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. there are, however, no adequate and well-controlled studies in pregnant women. animal reproduction studies are not always predictive of human response. general consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. the more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. there are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. safety and efficacy in children have not been established.